
ESMO/LinkedIn
Jun 26, 2025, 09:14
Targeted and Immunotherapy Strategies in NSCLC Explored by ESMO
ESMO – European Society for Medical Oncology shared on LinkedIn:
“Findings from the NeoADAURA and the CheckMate 816 provide novel insights on the role of neoadjuvant osimertinib and nivolumab in the perioperative setting adding to the current knowledge on how to integrate targeted and immunotherapy agents in the treatment planning.
Read the opinion by Marina Chiara Garassino in the ESMO Daily Reporter and learn what key questions remain unanswered.”
More posts featuring NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 26, 2025, 10:44
Jun 26, 2025, 10:37
Jun 26, 2025, 09:53
Jun 26, 2025, 09:36